Details for Patent: 7,060,828

Title:	Liposomal camptothecins and uses thereof
Abstract:	This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.
Inventor(s):	Madden; Thomas D. (Vancouver, CA), Semple; Sean C. (Vancouver, CA)
Assignee:	Inex Pharmaceuticals Corporation (Burnaby, CA)
Filing Date:	Jun 29, 2001
Application Number:	09/896,811
Claims:	1. A liposomal topotecan unit dosage form, said unit dosage form comprising: a lipid; and a topotecan dosage of 0.01 mg/M.sup.2/dose to 7.5 mg/M.sup.2/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by weight of 0.05 to 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol. 2. A method of treating solid tumors in a mammal, said method comprising: administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising 0.01 mg/M.sup.2/dose to 7.5 mg/M.sup.2/dose of topotecan for an interval regime, wherein said liposomal topotecan formulation has a drug:lipid ratio by weight of 0.05 to 0.2 and wherein said liposome comprises a mixture of sphingomyelin and cholesterol for a time and under conditions effective to reduce and/or delay growth of the solid tumor mass. 3. The method of treating solid tumors of claim 2, wherein said interval regime is at least once a week. 4. The method of treating solid tumors of claim 2, wherein said interval regime is at least once every two weeks. 5. The method of treating solid tumors of claim 2, wherein said interval regime is at least once every three weeks. 6. The method of treating solid tumors of claim 2, wherein said interval regime is once a day for at least two consecutive days. 7. A liposomal camptothecin unit dosage form, said unit dosage form comprising a lipid, a camptothecin dosage of from 0.015 mg/M.sup.2/dose to 1 mg/M.sup.2/dose and having a drug:lipid ratio by weight of 0.05 to 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol. 8. The liposomal topotecan unit dosage form of claim 1, wherein said drug:lipid ratio by weight is 0.05 to 0.15. 9. The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises sphingomyelin and cholesterol in a molar ratio of 70:30 to 40:45. 10. The liposomal topotecan unit dosage form of claim 1, comprising from 1 mg/M.sup.2/dose to 4 mg/M.sup.2/dose of topotecan.